Kasabach-Merritt phenomenon in an adult man with a tufted angioma and cirrhosis responding to radiation, bevacizumab, and prednisone.
BACKGROUND
Tufted angioma (TA) is a benign cutaneous vascular tumor that most commonly occurs in young children. TAs have rarely been reported in adults and/or arising within port-wine stains (PWS). Kasabach-Merritt phenomenon (KMP) is a life-threatening consumptive coagulopathy hypothesized to occur specifically in young children who develop either a TA or kaposiform hemangioendothelioma.


METHODS
Here we present a 52-year-old man with hepatitis C cirrhosis who presented with an extensive, painful vascular tumor involving the right side of his head, neck, and back that initially arose within a PWS.


RESULTS
He developed petechiae, severe thrombocytopenia, and a consumptive coagulopathy consistent with KMP. An incisional biopsy of his vascular tumor was compatible with a TA. Numerous treatments aimed at halting proliferation of his TA were attempted, with sustained improvement in his vascular tumor and platelet count achieved only after several courses of electron beam radiation therapy in association with corticosteroids and bevacizumab.


CONCLUSIONS
To our knowledge, this represents the first report of KMP in an adult man associated with TA and challenges previous hypotheses arguing that KMP occurs only in children. We offer our own hypothesis concerning how, in extremely rare circumstances, this life-threatening consumptive coagulopathy may occur in adults. Electron beam radiation therapy in association with corticosteroids can be an effective treatment in these rare patients.
Departments of Dermatology and Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.
Anthony P
AP
Fernandez
Aaron
A
Wolfson
Eugene
E
Ahn
Jennifer C
JC
Maldonad
Javier
J
Alonso-Llamazares
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006391:Hemangioma / Q000188:drug therapy* / Q000532:radiotherapy*; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D059885:Kasabach-Merritt Syndrome / Q000188:drug therapy* / Q000532:radiotherapy*; D008103:Liver Cirrhosis / Q000821:virology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000068258:Bevacizumab; D011241:Prednisone